Company Research

Bristol-Myers Squibb Company (BMY)

Scanner score: 48.00Price: $61.35ROE: 44.01%Margin of safety: 53.64%

First analyzed: 2026-11-18

Part 1

Company Overview

Bristol Myers Squibb is a global, patent-protected biopharmaceutical company with a strong oncology and hematology franchise, meaningful cardiovascular and immunology businesses, and a rapidly growing newer-product portfolio; its long-term position depends on replacing large legacy-product revenues as generic competition and patent expirations intensify.

Business Model

Overview

  • Fact: BMS operates as one reportable segment covering drug discovery, development, licensing, manufacturing, marketing, distribution and sales.
  • Fact: The company focuses primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience.
  • Fact: BMS earns revenue mainly from selling prescription medicines, supplemented by alliance revenues, royalties and other licensing-related revenue.

Revenue Mix

  • Fact: In fiscal 2025, total revenue was $48.194 billion.
  • Fact: Net product sales were $46.756 billion, or approximately 97% of total revenue; alliance revenue was $447 million and other revenue was $992 million.
  • Fact: BMS reported $26.409 billion from its Growth Portfolio and $21.785 billion from its Legacy Portfolio in 2025. The Growth Portfolio represented approximately 55% of revenue and the Legacy Portfolio approximately 45%.
  • Fact: The Growth Portfolio included Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy and other growth products.
  • Fact: Major Legacy Portfolio products included Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, Abraxane and other mature brands.

Geographic Mix

  • Fact: 2025 revenue was $33.279 billion in the United States, $13.828 billion internationally and $1.087 billion from other sources, including certain alliance and other revenue categories.
  • Fact: Approximate geographic mix was 69% United States, 29% international and 2% other.
  • Fact: No single country outside the United States contributed more than 10% of total revenue in 2025.
  • Interpretation: BMS is primarily exposed to the U.S. pharmaceutical market, where pricing, rebates, Medicare policy and government reimbursement have an outsized effect on results.

Customers And Distribution

  • Fact: Products are sold principally to wholesalers, distributors and specialty pharmacies, with additional sales to retailers, hospitals, clinics, government agencies and patients.
  • Fact: Orders are generally fulfilled within a few days, leaving minimal order backlog.
  • Fact: In some international markets, BMS uses distributors for logistics, regulatory support, pharmacovigilance and commercial activities.

Recurring Or Cyclical

  • Fact: Pharmaceutical demand is generally not seasonal, although BMS typically experiences first-quarter channel-inventory unwinding after fourth-quarter buildup.
  • Interpretation: Revenue is recurring in the sense that patients and physicians continually use established medicines, but it is not subscription-like. Product revenue is lifecycle-driven and can be highly cyclical around patent expiry, generic entry, regulatory decisions, clinical outcomes, reimbursement changes and new-product launches.
  • Interpretation: BMS has relatively defensive demand for medically necessary therapies, but the durability of revenue from any individual product is limited by market exclusivity.

History

Origins And Merger

  • Fact: Bristol-Myers traces its corporate history to a New York business started in 1887 and was incorporated as Bristol-Myers Company in 1933.
  • Fact: Bristol-Myers changed its name to Bristol-Myers Squibb Company in 1989 following a merger with Squibb.

Major Acquisitions And Pivots

  • Fact: The November 2019 acquisition of Celgene, valued at approximately $80.3 billion, was the defining modern transformation of BMS. It added major hematology and oncology assets, including Revlimid, Pomalyst, Abraxane and the development platform that contributed to Breyanzi and other products.
  • Fact: In 2020, BMS acquired MyoKardia for approximately $13.1 billion, obtaining mavacamten, later commercialized as Camzyos for obstructive hypertrophic cardiomyopathy.
  • Fact: In 2022, BMS acquired Turning Point Therapeutics for approximately $4.1 billion in cash, adding the precision-oncology asset repotrectinib, later commercialized as Augtyro.
  • Fact: In January 2024, BMS completed its acquisition of Mirati Therapeutics, adding Krazati and other oncology assets.
  • Fact: In February 2024, BMS acquired RayzeBio for approximately $4.1 billion, adding an actinium-based radiopharmaceutical platform and the development-stage asset RYZ101.
  • Fact: In March 2024, BMS acquired Karuna Therapeutics for approximately $14.0 billion, obtaining Cobenfy, a novel schizophrenia medicine that received U.S. approval in September 2024.
  • Fact: In May 2025, BMS acquired 2seventy bio for approximately $287 million, obtaining full U.S. rights to Abecma.

Milestones

  • Fact: Opdivo became the central product of BMS's immuno-oncology strategy and remains the company's largest Growth Portfolio product.
  • Fact: The company expanded beyond traditional oncology through Camzyos in cardiovascular disease, Zeposia and Sotyktu in immunology, and Cobenfy in neuroscience.
  • Fact: Cell therapy became an important strategic capability through Breyanzi and Abecma, supported by internal manufacturing investments and external partnerships.
  • Fact: BMS has increasingly used acquisitions, licensing and partnerships to replenish its pipeline and offset expected losses of exclusivity in mature products.

Leadership

  • Fact: Christopher Boerner, Ph.D., became chief executive officer in November 2023 and was identified as chair and CEO in the 2025 Form 10-K filed in February 2026.
  • Interpretation: The leadership transition placed a comparatively younger executive team in charge during a period requiring simultaneous cost control, pipeline execution, commercial launches and large-scale portfolio renewal.

Strengths and Moat

Competitive Advantages

  • Fact: BMS owns or controls a portfolio of widely used branded medicines with regulatory exclusivity, patent protection, physician familiarity and established reimbursement access.
  • Fact: The company has deep clinical-development, regulatory, manufacturing and commercial capabilities across oncology, hematology, immunology, cardiovascular medicine and neuroscience.
  • Fact: BMS spent $9.951 billion on research and development in 2025, including $1.341 billion on research and $4.550 billion on drug development.
  • Fact: The company has global commercial infrastructure and manufacturing operations in the United States, Puerto Rico, the Netherlands, Ireland and Switzerland.
  • Fact: BMS combines internal research with a distributed external model involving licensing, acquisitions, alliances and academic or biotechnology partnerships.
  • Interpretation: Its strongest advantage is not a single permanent technological monopoly but the ability to discover, acquire, develop, manufacture and commercialize complex medicines at global scale.

Main Competitors

  • Fact: BMS competes with large research-based pharmaceutical companies, smaller biotechnology companies, generic manufacturers and companies developing alternative treatment technologies.
  • Interpretation: Key competitive pressure comes from Merck in immuno-oncology, AbbVie, Johnson & Johnson and other companies in hematology, Pfizer through the Eliquis alliance and cardiovascular markets, Novartis and Roche in oncology and cell therapy, and numerous biotechnology companies in precision oncology, radiopharmaceuticals and neuroscience.
  • Interpretation: The exact competitor set varies by product and indication; BMS may compete against both global pharmaceutical companies and focused biotechnology firms with newer or more targeted therapies.

Where Bms Wins

  • Fact: BMS has commercial scale in oncology and hematology, including Opdivo, Yervoy, Breyanzi and other products.
  • Fact: The company has demonstrated an ability to convert external innovation into commercial products through acquisitions such as MyoKardia, Turning Point and Karuna.
  • Fact: BMS has broad clinical-development and regulatory capabilities that support additional indications, geographic launches and combination therapies.
  • Interpretation: BMS is strongest where treatment complexity, clinical evidence, manufacturing capability and physician adoption matter more than low-cost production.

Where Bms Loses Or Is Vulnerable

  • Fact: Generic competition materially reduced revenue from Revlimid, Pomalyst, Sprycel and Abraxane in 2025.
  • Fact: BMS states that the U.S. market can experience rapid revenue declines after loss of exclusivity.
  • Fact: Opdivo operates in an intensely competitive immuno-oncology market, with competition from other checkpoint inhibitors, combination regimens and new therapies.
  • Fact: Abecma faced lower U.S. demand in 2025 because of increased competition in BCMA-targeted therapies.
  • Fact: U.S. pricing and rebate pressure reduced average net selling prices in 2025, while government programs and Medicare policy remain significant risks.
  • Interpretation: BMS's large revenue base is both an asset and a liability: blockbuster concentration creates substantial cash generation but also creates large replacement requirements when patents expire.

Moat Durability

  • Interpretation: The moat is strong but not permanent. Patents, regulatory exclusivity, clinical data, manufacturing know-how, physician relationships, scale and global distribution create meaningful barriers to entry.
  • Interpretation: The moat is more durable for complex biologics, cell therapies, radiopharmaceuticals and medicines supported by differentiated clinical evidence than for conventional small-molecule products approaching generic entry.
  • Fact: BMS disclosed that generic versions of several mature products have already entered markets or are expected to enter, and that generic competition for Eliquis is a major future issue.
  • Interpretation: Long-term moat durability depends on sustained R&D productivity and disciplined business development. Acquisitions can replenish the portfolio, but they also create execution, valuation, integration and balance-sheet risks.
  • Overall assessment: BMS has a wide operating platform and valuable current franchises, but its economic moat should be viewed as renewable rather than static. The critical test is whether new products such as Cobenfy, Camzyos, Reblozyl, Breyanzi, Opdualag, Krazati and other pipeline assets can offset the erosion of Eliquis and legacy hematology revenues.

Bottom line

Bristol Myers Squibb is a global biopharmaceutical company that monetizes patented and regulated medicines, with approximately $48.2 billion of 2025 revenue and a portfolio spanning oncology, hematology, immunology, cardiovascular disease and neuroscience. Its differentiation comes from clinical and commercial scale, a deep oncology platform, complex manufacturing capabilities and a demonstrated ability to acquire and develop external innovation. The most important long-term issue is portfolio renewal: BMS must convert its newer products and pipeline into durable cash flows before generic competition and patent expirations materially shrink its legacy franchises.

Advertisement

Part 2

Updated 2026-11-18

Current Situation & Why the Stock Is in a Rut

BMY is stuck because investors are discounting a real earnings transition: rapid generic erosion and Medicare pricing pressure in the legacy portfolio must be offset by newer products and pipeline launches, even though 2026 operating results have so far improved and guidance has been raised.

Recent Performance

Stock Context

  • The supplied scanner snapshot lists BMY at $59.59 on October 6, 2026, with a P/E of 13.1. Independent market data showed a 3.83% decline on October 5, 2026, after the stock had fallen from $64.13 on September 30 to $58.81 on October 5.
  • The stock remains below its reported 52-week high of $68.64. It is not a straightforward collapse: independent data showed approximately 9% year-to-date price appreciation as of October 5, but a roughly 12% one-month decline.

Last Three Reports

  • Period

    Q2 2026

    Date

    July 30, 2026

    Revenue

    $12.973 billion, up 6% year over year and 5% excluding foreign exchange.

    Margins

    GAAP gross margin was 71.3%, down from 72.5% in Q2 2025; non-GAAP gross margin was 71.4%, down from 72.6%. Management attributed the decline primarily to product mix.

    Eps

    GAAP EPS was $1.62 versus $0.64 in Q2 2025; non-GAAP EPS was $2.04 versus $1.46.

    Expectations

    A secondary earnings tracker reported adjusted EPS expectations of approximately $1.59 and revenue expectations of approximately $11.75 billion, implying a beat. The company itself does not publish analyst consensus estimates, so the consensus comparison is secondary-source data.

    Guidance

    BMS raised 2026 revenue guidance from approximately $46.0-$47.5 billion to $49.0-$50.0 billion and non-GAAP EPS guidance from $6.05-$6.35 to $6.75-$7.00. It also raised projected 2026 Eliquis revenue growth from 10%-15% to 20%-25%.

    Interpretation

    The quarter was operationally strong, but the market remained focused on the durability of Eliquis, the legacy-product decline, lower gross margins, and whether pipeline assets can support growth after the next patent and pricing pressures.

  • Period

    Q1 2026

    Date

    April 30, 2026

    Revenue

    $11.489 billion, up 3% year over year and 1% excluding foreign exchange.

    Margins

    GAAP gross margin fell to 70.2% from 72.9%; non-GAAP gross margin fell to 70.3% from 73.1%, primarily because of product mix.

    Eps

    GAAP EPS was $1.31 versus $1.20; non-GAAP EPS was $1.58 versus $1.80. Non-GAAP EPS declined 12% year over year despite revenue growth.

    Expectations

    A secondary tracker reported consensus adjusted EPS of approximately $1.44, while another tracker showed approximately $1.43. BMS actual non-GAAP EPS was $1.58. A reliable primary-source consensus figure was not available.

    Guidance

    BMS reaffirmed 2026 revenue guidance of approximately $46.0-$47.5 billion and non-GAAP EPS guidance of $6.05-$6.35, saying results were trending toward the upper end. Eliquis revenue growth guidance was 10%-15%.

    Interpretation

    The quarter showed the central transition problem: the Growth Portfolio grew 12%, but the Legacy Portfolio fell 6%, and lower margins plus higher investment spending weakened adjusted EPS.

  • Period

    Q4 and full year 2025

    Date

    February 5, 2026

    Revenue

    Q4 revenue was $12.502 billion, up 1% year over year. Full-year revenue was $48.194 billion, essentially flat year over year.

    Margins

    The company guided to approximately 69%-70% non-GAAP gross margin for 2026, below the higher margin profile implied by the prior portfolio mix.

    Eps

    Q4 GAAP EPS was $0.53 and non-GAAP EPS was $1.26, with both figures affected by a net $0.60-per-share impact from acquired IPRD charges and licensing income. Full-year GAAP EPS was $3.46 and non-GAAP EPS was $6.15.

    Expectations

    Consensus data conflict materially: one secondary tracker reported $1.23 of adjusted EPS expected, while another reported $1.65. Revenue expectations ranged from approximately $12.24-$12.28 billion. The actual result of $1.26 and $12.50 billion is therefore best described as a revenue beat and an EPS result that was either a small beat or a significant miss depending on the tracker. The actual BMS figures are more reliable than the conflicting consensus estimates.

    Guidance

    Initial 2026 guidance called for revenue of approximately $46.0-$47.5 billion and non-GAAP EPS of $6.05-$6.35, implying lower revenue than 2025 and a decline from 2025 adjusted EPS.

    Interpretation

    The initial guidance reset was a major reason the stock remained under pressure: management explicitly forecast a 12%-16% decline in Legacy Portfolio revenue, while the Growth Portfolio had to fund the transition.

Specific Dated Pressure Events

  • Date

    February 5, 2026

    Event

    BMS issued 2026 guidance below 2025 revenue and adjusted EPS levels, while forecasting a 12%-16% decline in Legacy Portfolio revenue.

    Why It Mattered

    The guidance highlighted the size and timing of the patent and generic erosion problem even though Growth Portfolio revenue was growing.

  • Date

    January 1, 2026

    Event

    The negotiated Medicare maximum fair price for Eliquis took effect.

    Why It Mattered

    Eliquis is BMS's largest product and the new pricing framework creates a direct pressure on U.S. Medicare economics. BMS's 2025 Form 10-K identifies this as a material risk.

  • Date

    October 5, 2026

    Event

    Leerink Partners downgraded BMY from Outperform to Market Perform and cut its price target from $73 to $59, citing pipeline concerns.

    Why It Mattered

    The downgrade coincided with a reported 3.83% one-day share-price decline and reinforced the market's concern that the pipeline may not fully offset the future revenue cliff.

The Bear Case

Company Specific Problems

  • The Legacy Portfolio remains in decline. In Q1 2026 it fell 6% year over year, and in Q2 it fell 4%; generics across Revlimid, Pomalyst, Sprycel, Abraxane and other mature products more than offset Eliquis growth.
  • Eliquis concentration is both a current strength and a future risk. BMS expects 2026 Eliquis revenue growth of 20%-25%, but the product is subject to Medicare price negotiation, European generic pressure, and future U.S. generic litigation and launch risk.
  • The Growth Portfolio is growing, but several products are still relatively early in their commercial lifecycles. The business must execute simultaneously across Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Sotyktu, Cobenfy and other launches.
  • Gross margin declined year over year in both Q1 and Q2 2026. Management attributed this primarily to mix, but continued mix deterioration would limit the conversion of revenue growth into EPS and free cash flow.
  • Operating expenses are rising as BMS invests in pipeline programs and product launches. Q2 guidance increased 2026 operating expenses to approximately $16.5 billion.
  • The balance sheet remains heavily leveraged relative to an unlevered pharmaceutical company, with approximately $42.1 billion of long-term debt at June 30, 2026. Debt reduces flexibility for large acquisitions and increases sensitivity to interest costs.

Macro And Sector Headwinds

  • U.S. drug-price regulation and Medicare negotiation create structural pricing pressure across large-cap pharma, not just BMS.
  • Patent cliffs and generic competition are sector-wide issues. Investors are increasingly demanding proof that replacement products can grow before mature products decline.
  • Higher research, launch and regulatory costs can pressure margins even when revenue is stable.
  • Pharmaceutical stocks are sensitive to political risk involving drug pricing, reimbursement policy, tariffs, supply chains and international reference pricing. The magnitude of any future tariff effect on BMS is unverified.
  • The sector is increasingly valued on pipeline quality and late-stage clinical probability rather than current earnings alone, raising the penalty for trial delays or ambiguous data.

Valuation

  • At the supplied price of $59.59 and trailing P/E of 13.1, BMY is inexpensive versus many large-cap growth-oriented pharmaceutical companies but is not obviously distressed on earnings alone.
  • A secondary peer comparison published in late 2025 placed BMY around 11.5 times forward EPS, versus approximately 10.6 times for GSK and 10.5 times for Merck, while Pfizer was materially higher on that dataset. The figures are dated and methodology-dependent, so they should be treated as directional rather than current.
  • BMY's low valuation reflects an earnings-quality discount: part of current cash flow comes from products facing known erosion, while future earnings depend on successful launches and clinical development.
  • The scanner's reported dividend yield of 429.0% is not credible and is treated as a data error. BMS's 2026 annualized dividend was $2.52 per share; at $59.59, that implies an approximate yield of 4.2%, not 429.0%.

Analyst And Short Interest

  • The most notable recent negative action was Leerink's October 5, 2026 downgrade to Market Perform with a $59 target from $73.
  • Other negative or cautious actions included UBS and Jefferies downgrades on August 5, 2026, according to secondary analyst-rating databases. These should be treated as unverified at the original research-note level.
  • Analyst opinion is divided rather than uniformly bearish. Secondary compilations showed targets ranging from $40 to $82, with several Buy ratings but a large number of Hold ratings.
  • Short interest was approximately 41.97 million shares as of September 15, 2026, or 2.06% of public float, with roughly 5.8 days to cover. This is meaningful but not an extreme short-interest setup and does not by itself indicate a heavily shorted value trap.

Turnaround or Value Trap?

Bull Case

  • The Growth Portfolio is already demonstrating strong momentum: revenue increased 12% in Q1 and 15% in Q2 2026.
  • Q2 results were strong enough for BMS to raise both revenue and adjusted EPS guidance, reducing the probability of an immediate earnings deterioration scenario.
  • Eliquis growth materially exceeded prior expectations in Q2, and BMS raised 2026 Eliquis growth guidance to 20%-25%.
  • The pipeline has multiple potential catalysts, including mezigdomide, iberdomide, Sotyktu, Camzyos, Cobenfy and oncology programs. Positive late-stage data or regulatory approvals could cause the market to extend the earnings multiple.
  • A P/E near 13 and a dividend yield near 4.2% provide valuation support if the company can stabilize earnings and maintain cash generation.
  • Free cash flow in the supplied scanner snapshot was $12.845 billion, which, if verified against the next filing, would support dividends, debt reduction and continued pipeline investment.

Bear Case

  • The current valuation may be a value trap if the market is correctly anticipating several years of Eliquis and legacy-product erosion.
  • The Q2 guidance increase could partly reflect better near-term Eliquis performance rather than a durable improvement in the long-term portfolio mix.
  • Pipeline success is uncertain, and a failed pivotal trial, regulatory delay, safety signal or weak launch could leave BMS with fewer replacement products when older brands decline.
  • Gross-margin compression and rising R&D and launch spending could prevent revenue growth from translating into earnings growth.
  • The company may need additional business development or acquisitions to replace lost revenue, but leverage limits the ability to pursue large deals without increasing financial risk.
  • The recent Leerink downgrade shows that investors may value BMS on pipeline credibility rather than on current-year earnings, making the stock vulnerable to negative clinical or regulatory news.

What Needs To Happen For Recovery

  • Growth Portfolio revenue should continue growing at a double-digit rate while Legacy Portfolio declines moderate.
  • Eliquis should meet or exceed the raised 20%-25% 2026 growth outlook without an unexpectedly sharp deterioration in net pricing.
  • Gross margin should stabilize near or above the 2026 guidance range rather than continuing to fall.
  • BMS should deliver successful pivotal readouts and regulatory progress for major pipeline assets, especially mezigdomide, iberdomide and oncology programs.
  • Adjusted EPS and free cash flow should grow after 2026 rather than merely benefiting from favorable product timing or one-time accounting items.
  • Debt should decline or remain controlled while the dividend remains covered by recurring free cash flow.

Key Catalysts And Dates

  • Date

    October 29, 2026

    Catalyst

    BMS is scheduled to report Q3 2026 results.

    Metrics To Watch

    • Total revenue and Growth Portfolio revenue
    • Eliquis worldwide revenue and net pricing
    • Legacy Portfolio erosion
    • GAAP and non-GAAP gross margin
    • Adjusted EPS versus the $6.75-$7.00 full-year outlook
    • Any change to 2026 guidance
  • Date

    Second half of 2026

    Catalyst

    BMS has identified multiple pivotal pipeline readouts and regulatory milestones.

    Metrics To Watch

    • Probability-adjusted value of late-stage assets
    • Regulatory decisions and label expansions
    • Commercial launch timing
    • Safety, efficacy and durability data
  • Date

    2027-2028

    Catalyst

    Additional Medicare negotiation and patent-related pressures become more important, including Pomalyst pricing pressure from 2027 and further exposure to negotiated pricing and generic competition.

    Metrics To Watch

    • Net price erosion
    • Eliquis U.S. prescription and revenue trends
    • Generic launch timing
    • Legacy Portfolio contribution to operating cash flow

Signal For Turn

  • Two or more consecutive quarters of Growth Portfolio growth above 10% with stable or improving gross margin.
  • Legacy Portfolio decline narrowing without relying solely on Eliquis.
  • Adjusted EPS growth and free-cash-flow growth after accounting for R&D and launch investments.
  • Positive pivotal data that materially increases expected 2028-2030 revenue.
  • A sustained reduction in net debt and no dividend coverage deterioration.

Evidence Assessment

Classification

Mixed, but currently more consistent with a temporary-to-transitional problem than a fully structural business failure.

Why

  • The evidence against a near-term collapse is strong: Q1 and Q2 2026 revenue grew, Growth Portfolio revenue grew at double-digit rates, Q2 EPS exceeded the prior-year period, and management raised full-year guidance.
  • The evidence for a structural challenge is also substantial: the Legacy Portfolio is declining, Eliquis faces policy and patent risks, margins are falling, leverage is high, and the pipeline must replace a large amount of mature-product revenue.
  • The stock's recent weakness appears to reflect a valuation and confidence reset rather than a deterioration in the latest reported quarter. The October 5, 2026 downgrade and pipeline concerns were more important recent pressure points than the Q2 operating results.
  • The evidence favors a transitional turnaround thesis only if pipeline execution and post-2026 EPS growth are demonstrated. Without that evidence, the low P/E can remain justified as compensation for patent, pricing and execution risk.

Confidence

Moderate. Company financial figures and scheduled dates are supported by BMS releases, SEC filings and the investor-relations calendar. Current valuation, analyst actions, consensus estimates, short interest and price-performance figures rely partly on secondary databases and may differ by calculation date or methodology.

Bottom line

Bristol Myers Squibb is a large pharmaceutical company transitioning from mature drugs such as Eliquis, Revlimid, Pomalyst and Sprycel toward newer growth products and pipeline assets. The stock is stuck because investors see real current growth but remain concerned that patent erosion, Medicare pricing, margin pressure and leverage could overwhelm the replacement pipeline after 2026. The next major test is the October 29, 2026 Q3 report, with particular attention to Growth Portfolio growth, Eliquis net pricing, legacy-product erosion, gross margin, free cash flow and any evidence that late-stage pipeline assets can support durable post-2026 EPS growth.

Advertisement
Advertisement

Research history

The current situation refreshes after a gap or at the 30-day consecutive Top-10 refresh point. Previous analyses are retained.